Results 231 to 240 of about 9,057,173 (269)
Thrombosis and Haemostasis, 1965 Summary1. Methods have been developed for the preparation of factor VII free of prothrombin and factor X, and of factor X with only a very low contamination with factor VII.2. Factors VII and X could be found with one stage methods in purified prothrombin prepared according to Seegers.3. Purified prothrombin was chromatographed on DE AE-cellulose.
Deutsch E, Lechner K
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Survey of Ophthalmology, 2019
A 45-year-old white woman presented with chronic bilateral, painless, progressive, peripheral vision loss. She was found to have bilateral optic atrophy and nonenhancing multifocal white matter lesions on magnetic resonance imaging of the brain. Cerebrospinal fluid analysis showed an elevated level of myelin basic protein.
Muhammad Musab, Shamim +3 more
openaire +2 more sources
A 45-year-old white woman presented with chronic bilateral, painless, progressive, peripheral vision loss. She was found to have bilateral optic atrophy and nonenhancing multifocal white matter lesions on magnetic resonance imaging of the brain. Cerebrospinal fluid analysis showed an elevated level of myelin basic protein.
Muhammad Musab, Shamim +3 more
openaire +2 more sources
Acta Haematologica, 1974
In two patients with the abnormal factor X (factor X Friuli) coagulation disorder a multiple tooth extraction was carried out immediately after the transfusion. X of 4 U of factor X concentrate (Bebulin) equivalent to 2,000 ml of normal plasma. No bleeding was noted. The half-life of the exogeneous component was 30 and 28 h, respectively.
Antonio Girolami, L. De Marco, G. Molaro
openaire +3 more sources
In two patients with the abnormal factor X (factor X Friuli) coagulation disorder a multiple tooth extraction was carried out immediately after the transfusion. X of 4 U of factor X concentrate (Bebulin) equivalent to 2,000 ml of normal plasma. No bleeding was noted. The half-life of the exogeneous component was 30 and 28 h, respectively.
Antonio Girolami, L. De Marco, G. Molaro
openaire +3 more sources
Expert Opinion on Investigational Drugs, 2003
Factor X plays a central role in coagulation, being the point of convergence of the extrinsic and intrinsic pathways of blood clotting. It may also act as one of the links between the coagulation and inflammatory pathways. These findings suggest that factor X may represent an attractive target for a new antithrombotic drug. Indeed, a factor X inhibitor,
Gregory Y.H. Lip +2 more
openaire +3 more sources
Factor X plays a central role in coagulation, being the point of convergence of the extrinsic and intrinsic pathways of blood clotting. It may also act as one of the links between the coagulation and inflammatory pathways. These findings suggest that factor X may represent an attractive target for a new antithrombotic drug. Indeed, a factor X inhibitor,
Gregory Y.H. Lip +2 more
openaire +3 more sources
Blood Reviews, 2002
Factor X is one of the vitamin K-dependent serine proteases. It plays a crucial role in the coagulation cascade, as the first enzyme in the common pathway of thrombus formation. The gene for factor X maps to the long arm of chromosome 13, approximately 2.8 kb downstream of the factor VII gene.
James Uprichard, David J. Perry
openaire +3 more sources
Factor X is one of the vitamin K-dependent serine proteases. It plays a crucial role in the coagulation cascade, as the first enzyme in the common pathway of thrombus formation. The gene for factor X maps to the long arm of chromosome 13, approximately 2.8 kb downstream of the factor VII gene.
James Uprichard, David J. Perry
openaire +3 more sources
Seminars in Thrombosis and Hemostasis, 2009
Factor X (FX) deficiency is a rare, recessively inherited bleeding disorder representing 10% of all rare bleeding diseases and affecting 1 in every 1,000,000 people. Its clinical presentation places FX deficiency among the most severe of the rare coagulation defects, typically including hemarthroses, hematomas, and umbilical cord, gastrointestinal, and
Marzia Menegatti, Flora Peyvandi
openaire +3 more sources
Factor X (FX) deficiency is a rare, recessively inherited bleeding disorder representing 10% of all rare bleeding diseases and affecting 1 in every 1,000,000 people. Its clinical presentation places FX deficiency among the most severe of the rare coagulation defects, typically including hemarthroses, hematomas, and umbilical cord, gastrointestinal, and
Marzia Menegatti, Flora Peyvandi
openaire +3 more sources
The Factor‐X Defect: Recognition of Abnormal Forms of Factor X
British Journal of Haematology, 1970Summary. Six patients with the ‘Factor‐X defect’ have been investigated. At least five different forms of the defect were recognized by the use of the following laboratory tests: the kaolin cephalin clotting time as a measure of intrinsic clotting, the factor‐X assay employing either brain extract or Russell's viper venom, and the neutralization of a ...
A. Lurie +3 more
openaire +3 more sources
Abnormal Factor X (Factor X Friuli) Coagulation Disorder
Acta Haematologica, 1973A new case with the abnormal factor X (factor X Friuli) coagulation disorder is presented: a 32-year- old female who was born outside Friuli and who complained of a bleeding tendency since childhood.
A. Girolami +3 more
openaire +3 more sources
One Missense Mutation in the Factor X Gene Causing Factor X Deficiency—Factor X Kanazawa
International Journal of Hematology, 2001We investigated the molecular basis of factor X deficiency in a Japanese patient whose factor X activity and antigen level were 45% and 50% of normal control values, respectively. All exons and intron/exon junctions of the factor X gene were studied using a strategy combining polymerase chain reaction (PCR) amplification and nonradioactive single ...
Tomoe Mizutani +8 more
openaire +3 more sources
Factor X Vorarlberg, A New Variant of Hereditary Factor X Deficiency [PDF]
Thrombosis and Haemostasis, 1979 The proposita, a 56 years old woman, has a mild bleeding tendency. Prothrombin time was 112 sec (control 17.0 sec), stypven time 13.7 sec (control 11.5 sec) and APTT 54 sec (control 40 sec). Factor I, II (funct.and imm.), V, VII, VIII, IX, XI, XII, AT III were normal. - Factor X activity was < 1% by extrinsic system assay (tissue thromboplastin), 12%
G. Mähr +3 more
openaire +1 more source